GlassScriptPhysician profile
James R Thomas
NPI 1578566410
$9,232.42
in general payments reported to CMS, 2019-2025
67 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $490 · 2021: $985 · 2022: $1,190 · 2023: $1,601 · 2024: $1,543 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.10 |
| Education | $406.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $869.77 | 2019-2025 | |
| Pfizer INC. | $603.92 | 2019-2025 | |
| Daiichi Sankyo INC. | $557.68 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Janssen Biotech, INC. | $495.43 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Gilead Sciences, INC. | $412.66 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $411.30 | 2020-2024 | Opdivo |
| Amgen INC. | $395.36 | 2019-2023 | Lumakras, Kyprolis |
| Astrazeneca Pharmaceuticals LP | $359.04 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Genentech USA, INC. | $340.42 | 2019-2025 | Polivy, Tecentriq, Itovebi |
| Astellas Pharma US INC | $339.83 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Incyte Corporation | $281.34 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $279.57 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Myriad Genetic Laboratories, INC. | $248.96 | 2021-2024 | Myrisk |
| Eisai INC. | $207.93 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $180.89 | 2020-2025 | Libtayo |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.